Status:
UNKNOWN
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.
Lead Sponsor:
Mabaret Al-Asafara Hospitals
Conditions:
Drug Toxicity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Acute Valproic acid (VPA) toxicity is an emergency condition which may commonly present with central nervous system (CNS) depression(5). In mild poisoning, associated with VPA ingestions of 200 mg/kg,...
Detailed Description
JUSTIFICATION AND SIGNIFICANCE: Valproic acid (VPA) -a branched chain carboxylic acid- introduced by the Food and Drug Administration in 1978 for the treatment of seizure disorders(1). In the followi...
Eligibility Criteria
Inclusion
- Patients with VPA toxicity will be included if aged 18 years or more. The patient himself/herself should provide informed consent; a family member may take place only if there is an altered mentation that may hinder such procedure.
Exclusion
- Patients will be excluded if presenting one hour following VPA ingestion and were administered AC for gastric decontamination, as it may decrease VPA bioavailability.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04671589
Start Date
June 1 2021
End Date
December 1 2022
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria University hospitals
Alexandria, Egypt